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Identity 
Other names: FKHL15, FOXE2, HFKH4, HFKL5, 
TITF2, TTF-2, TTF2 




The gene consists of 1 exon and is intronless; the 5' and 
the 3' parts of the exon are non-coding. 
Transcription 
3461 bp transcript with a 1121 bp of coding sequence. 
Protein 
Description 
The FOXE1 protein is 373-amino acid long and its 
molecular weight is 42 kDa. It contains a forkhead 
DNA-binding domain, 2 putative nuclear localization 
signals (NLS) which flank the DNA-binding domain, 
and a polyalanine (polyA) stretch  
of variable length. Population-based studies found 
polymorphism of the polyA tract lengths varying from 
11 to 19 residues with the 14 as the most frequent allele 
(Venza et al., 2006; Macchia et al., 1999; Hishinuma et 
al., 2001; Tonacchera et al., 2004; Santarpia et al., 
2007; Carre et al., 2007). 
Expression 
In humans, FOXE1 is expressed at the embryonic 
Carnegie stage (CS) 15 in the thyroid primordium and
persists in the thyroid gland throughout development. 
At the same embryonic stage, FOXE1 is also detectable 
in the thymus and in the oropharyngeal epithelium. At 
11 weeks of development it is present in the trachel 
and esophageal epithelium (Trueba et al., 2005). 
In mice, FOXE1 is expressed at embryonic day E8.5 in 
the endoderm corresponding to the floor of the foregut, 
at E9.2-9.3 in the epithelium lining the anterior fegut 
and the posterior stomodeum, including the pharyngeal 
membrane, and in the migrating thyroid primordium 
and at E9.5 in the craniopharyngeal ectoderm involved 
in palate formation. Later, at E10.5 FOXE1 expression 
is transcribed along all the endoderm of the foregut 
lining the visceral pouch of the branchial arches 
(Zannini et al., 1997; Dathan et al., 2002). 
 
Schematic diagram of the human FOXE1 gene. 
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FOXE1 regulates the transcription of thyroglobulin 
(Tg) and thyroid peroxidase (TPO), and represses 
transcriptional activation of TTF-1 and PAX8 on the 
Tg and TPO promoters. The gene plays an important 
role in thyroid development, secondary palate closure 
and hair follicle morphogenesis. FOXE1 is also 
implicated in malignancy. 
Homology 
Member of the forkhead box E (FOXE) subfamily 
which itself is a part of the large FOX gene family of 
transcription factors, characterized by sharing a 
common 100 amino acid forkhead domain. FOXE 
proteins (FOXE-1, -2, -3, -4) are widely expressed in a
range of tissues, have diverse roles in development and 
metabolism and have been implicated in various forms 




Genome-wide association studies (GWAS) showed a 
significant correlation of the rs965513 variant located 
57-kb upstream to FOXE1 with follicular thyroid 
carcinoma (FTC) (Gudmundsson et al., 2009) as well 
as with sporadic or radiation-related papillary thyroid 
carcinoma (PTC) (Gudmundsson et al., 2009; 
Takahashi et al., 2010). A detailed analysis of the PTC-
risk conferring haplotype identified rs1867277 as a 
highly correlated putative functional variant within the 
FOXE1 promoter (Landa et al., 2009). Functional 
assays revealed that the rs1867277 G allele partially 
impairs the recruitment of USF1 and USF2 factors to 
the FOXE1 promoter and alters the expression status of 
the FOXE1 gene (Landa et al., 2009). 
Pancreatic cancer 
Disease 
Aberrant CpG methylation of FOXE1 was detected in 
pancreatic cancer cell lines and in a series of resect d 
primary pancreatic carcinomas (Sato et al., 2003) as 
well as in familial and sporadic pancreatic 
adenocarcinoma specimens (Brune et al., 2008). 
FOXE1 was also prevalently methylated in the surgical 
pancreatic juice of patients with pancreatic ductal 
adenocarcinoma, less frequently in samples of 
intraductal papillary mucinous neoplasms, but never in 




DNA hypermethylation events in the CpG islands of 
FOXE1 promoter were present in plasma samples from 
breast cancer patients (Weisenberger et al., 2008). 
Cutaneous squamous cell carcinoma 
(SCC) 
Disease 
A higher frequency of FOXE1 promoter 
hypermethylation was found in cutaneous SCCs (55%), 
as compared with the adjacent uninvolved skin (12%) 
and blood control samples (9%). FOXE1 methylation 
was frequently seen in association with a complete 
absence or downregulation of gene expression. 
Treatment with the demethylating agent 5-Aza-2'-
deoxycytidine resulted in profound reactivation of 
FOXE1 expression (Venza et al., 2010a). It was also
reported that expansions of the polyA tract (16 alanine) 




Homozygous, human loss-of-function mutations 
located within the forkhead domain of FOXE1 (A65V, 
S57N and R72S) cause the Bamforth-Lazarus 
syndrome, which includes congenital hypothyroidism, 
cleft palate and spiky hair, with or without choanal 
atresia, bifid epiglottis, and ocular hypertelorism, 
depending on the severity of the mutation (Clifton-
Bligh et al., 1998; Castanet et al., 2002; Baris et al., 
2006). In vitro studies showed the complete lack of 
DNA binding and transcriptional activity of A65V 
(Clifton-Bligh et al., 1998) and R102C (Baris et al., 
2006), and the partial preservation of function with the 
S57N (Castanet et al., 2002) mutant FOXE1 proteins, 
respectively. 
Non-syndromic cleft lip with or without 
cleft palate (NS CL/P) 
Disease 
Rare missense mutations in FOXE1 (A207V and 
D285V) have been associated with isolated clefting 
(Vieira et al., 2005). Fine-mapping association studies 
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showed genome-wide significant SNPs in or near 
FOXE1 region (rs3758249, rs4460498, rs1443434, 
rs993501) in CLP patients (Marazita et al., 2009; 
Moreno et al., 2009). Recently, the novel homozygous 
polymorphism C(-1204)G in the FOXE1 promoter 
region that prevented the binding of MYF-5, a 
myogenic regulatory factor essential for the muscle-
dependent craniofacial skeletal development and the 
fusion of primary and secondary palate, was found in 
non-syndromic CP patients (Venza et al., 2009). 
Premature ovarian failure (POF) 
Disease 
Variation in FOXE1 polyalanine length from the most 
frequently occurring 14 alanine allele to the 16 allele 
increases the risk of developing POF (Watkins et al., 
2006). 
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